2025-08-25 - Analysis Report
Okay, here's a report based on the provided data, structured as requested.

## TGTX (TG Therapeutics Inc) Stock Analysis

**TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.**

### 1. Performance vs. S&P 500 (VOO)

*   **Accumulated Return (TGTX):** 53.06%
*   **Accumulated Return (VOO):** 38.83%
*   **Absolute Difference:** 14.23%
*   **Relative Deviation (Current):** 11.9% (This indicates TGTX is currently positioned at the 11.9th percentile within its historical range relative to the S&P 500)

**Analysis:** TGTX has outperformed the S&P 500 (VOO) in terms of cumulative return. However, the relative deviation suggests that TGTX's outperformance is near the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | -6.0%  | 56.5% | -6.0%  | 1.0   | 1.3    |
| 2016-2018  | -8.0%  | 58.6% | -8.0%  | 1.0   | 0.7    |
| 2017-2019  | 74.0%  | 58.6% | 74.0%  | 1.0   | 1.8    |
| 2018-2020  | 402.0% | 58.6% | 402.0% | 1.0   | 8.2    |
| 2019-2021  | 125.0% | 63.5% | 124.0% | -0.1  | 3.0    |
| 2020-2022  | -76.0% | 70.4% | -65.0% | 0.1   | 1.9    |
| 2021-2023  | -350.0%| 70.4% | -360.0%| 0.0   | 2.7    |
| 2022-2024  | 71.0%  | 73.1% | 41.0%  | 0.1   | 4.8    |
| 2023-2025  | 60.0%  | 73.1% | 15.0%  | -0.0  | 4.7    |

**Table Analysis:**

*   **CAGR & MDD:** The table shows significant fluctuations in TGTX's Compound Annual Growth Rate (CAGR) and Maximum Drawdown (MDD) over different periods.  The CAGR ranges from highly negative (-350%) to extremely positive (402%). The MDD is consistently high, indicating substantial risk.
*   **Alpha:** The Alpha values mirror the CAGR trends, suggesting that TGTX's performance is strongly driven by its own specific factors rather than market-wide movements.
*   **Beta:** Beta values are close to 1 or even negative, suggesting that the stock's volatility is similar to or even counter to the overall market in some periods.
*   **Cap(B):** Market Cap (in Billions) fluctuates, reflecting the changing investor sentiment and company performance.

### 2. Recent Price Action

*   **Current Price:** $29.44
*   **Last Market Close:**
    *   Price: $29.445
    *   Previous Close: $28.77
    *   Change: +2.35% (Significant positive change)
*   **5-Day Moving Average:** $28.44
*   **20-Day Moving Average:** $29.85
*   **60-Day Moving Average:** $34.70

**Analysis:** The stock price has experienced a significant increase (2.35%) compared to the previous close.  The current price is above the 5-day moving average but below the 20-day and 60-day moving averages. This suggests a short-term upward trend but potentially facing resistance at the longer-term moving averages.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3377 (Low Risk)
*   **RSI:** 55.44 (Neutral - Neither overbought nor oversold)
*   **PPO:** 0.74 (Positive - indicating a possible upward trend)
*   **Hybrid Signal:** "cash_1%_Buy 80% of cash (149 shares - Caution - MRI:0.34)" - This suggests a buy signal with caution due to the MRI.  It recommends allocating 80% of available cash to purchase approximately 149 shares, while keeping a 1% cash reserve.
*   **Recent (20-day) Relative Deviation Change:** 0.6 (+) - Short-term increase.
*   **Expected Return (%):** -349.1 - This is a significantly negative expected return compared to the S&P 500 over a long-term (2+ years) investment horizon.

**Analysis:** The MRI indicates low market risk, which is a positive sign. The RSI is neutral. The PPO is positive, suggesting upward momentum. However, the significantly negative expected return is a major concern. The recent price surge and positive relative deviation change should be considered in light of the overwhelmingly negative long-term outlook.

### 4. Recent News & Significant Events

*   **[2025-08-22]** Major business developments, regulatory changes, or market events.
*   **[2025-08-24]** Analysts discussing recent performance and outlook.
*   **[2025-08-23]** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-08-21]** Market experts highlight risks and opportunities, advising monitoring.

**Analysis:** The news suggests that TGTX is currently subject to significant events and market attention, potentially explaining the recent volatility and price surge. Investors should closely monitor news releases and company announcements to understand the drivers behind these events.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-08-08 | 0.19   | 0.14 B$   |
| 2025-05-09 | 0.03   | 0.12 B$   |
| 2024-11-07 | 0.03   | 0.08 B$   |
| 2024-08-09 | 0.05   | 0.07 B$   |
| 2025-08-08 | 0.05   | 0.07 B$   |

**Analysis:**

*   **EPS:** There is a recent increase in EPS compared to previous periods.
*   **Revenue:** Revenue has also increased in the most recent quarter.
*   **Trend:** The company has shown improvements in both EPS and Revenue.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.14B   | 86.58%        |
| 2025-03-31 | $0.12B   | 87.14%        |
| 2024-12-31 | $0.11B   | 85.77%        |
| 2024-09-30 | $0.08B   | 88.86%        |
| 2024-06-30 | $0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-06-30 | $0.28B   | 10.20%   |
| 2025-03-31 | $0.24B   | 2.13%    |
| 2024-12-31 | $0.22B   | 10.49%   |
| 2024-09-30 | $0.19B   | 2.02%    |
| 2024-06-30 | $0.18B   | 3.87%    |

**Analysis:**

*   **Revenue:** Revenue has generally been increasing over the past few quarters.
*   **Profit Margin:** Profit margins are very high, consistently above 85%, suggesting good cost control.
*   **Equity:** Equity has also increased over time, indicating a stronger financial foundation.
*   **ROE:** ROE fluctuates significantly but is relatively high in some quarters, indicating good profitability relative to equity.

### 7. Overall Summary

TGTX shows a mixed picture.

*   **Positives:** Recent EPS and Revenue growth, high profit margins, increasing equity, and a recent price surge suggest potential short-term momentum. The MRI indicates low market risk.
*   **Negatives:** The significantly negative long-term expected return is a major red flag. The high MDD values highlight the stock's inherent risk.
*   **Considerations:** The recent news events and analyst discussions suggest that TGTX is subject to significant developments. Investors should conduct thorough due diligence, closely monitor news and company announcements, and carefully consider their risk tolerance before making any investment decisions.

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.
